2. Search Result
Search Result
Results for "

Lactate Dehydrogenase Inhibitor

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

2

Biochemical Assay Reagents

5

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W013032A
    Oxamic acid sodium
    Maximum Cited Publications
    58 Publications Verification

    Sodium oxamate

    		 Lactate Dehydrogenase Apoptosis Cancer
    Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .
    Oxamic acid sodium
  • HY-100681
    GSK2837808A
    40+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
    GSK2837808A
  • HY-Y0445A
    Sodium dichloroacetate
    25+ Cited Publications

    		 PDK-1 NKCC PDHK Reactive Oxygen Species (ROS) Apoptosis Cancer
    Sodium dichloroacetate is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor. Sodium dichloroacetate also stimulates pyruvate dehydrogenase (PDH) activity and works as a Na +-K +-2Cl − cotransporter (NKCC) inhibitor. Sodium dichloroacetate prevents the phosphorylation of the E1α subunit of PDC, promoting the entry of pyruvate into the mitochondria for oxidative metabolism, reducing lactate production, and simultaneously increasing the production of reactive oxygen species (ROS). Sodium dichloroacetate inhibits tumor cell proliferation and induces apoptosis. Sodium dichloroacetate is promising for research of cancers .
    Sodium dichloroacetate
  • HY-100742A
    (R)-GNE-140
    15+ Cited Publications

    		 Lactate Dehydrogenase Bacterial Cardiovascular Disease Infection Inflammation/Immunology Cancer
    (R)-GNE-140 is a potent inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. (R)-GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. (R)-GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression. (R)-GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer .
    (R)-GNE-140
  • HY-16214
    FX-11
    25+ Cited Publications

    LDHA Inhibitor FX11

    		 Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS) Cancer
    FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .
    FX-11
  • HY-W013032
    Oxamic acid
    55+ Cited Publications

    Oxamidic acid

    		 Lactate Dehydrogenase Apoptosis Cancer
    Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .
    Oxamic acid
  • HY-W040118
    Galloflavin
    10+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .
    Galloflavin
  • HY-111108
    LDH-IN-1
    2 Publications Verification

    		 Lactate Dehydrogenase Cancer
    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
    LDH-IN-1
  • HY-147216
    AXKO-0046
    5 Publications Verification

    		 Lactate Dehydrogenase Cancer
    AXKO-0046, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor.AXKO-0046 has LDHB inhibitory activity with an EC50 value of 42 nM.AXKO-0046 can be used for the research of cancer metabolism .
    AXKO-0046
  • HY-100742
    GNE-140 racemate
    5+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    GNE-140 racemate (Compound 28) is an external racemization mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B), and it is also an interconformational isomer of GNE-140 (HY-118241). GNE-140 racemate is also an effective lactate dehydrogenase (LDH) inhibitor, with the IC50 values for LDHA and LDHB being 9 nM and 30 nM respectively. GNE-140 racemate can be used in cancer research .
    GNE-140 racemate
  • HY-18968
    AZ-33
    1 Publications Verification

    LDHA-IN-4

    		 Lactate Dehydrogenase Cancer
    AZ-33 (LDHA-IN-4) (compound 33) is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 0.5 μM and a Kd of 0.093 μM .
    AZ-33
  • HY-124113
    4'-Bromo-resveratrol

    4′‐BR

    		 Sirtuin Apoptosis Caspase Lactate Dehydrogenase GLUT Metabolic Disease Inflammation/Immunology Cancer
    4'-Bromo-resveratrol (4′‐BR) is a dual SIRT1/SIRT3 inhibitor with an IC50 of 0.2 mM for both targets. 4'-Bromo-resveratrol induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhiibits proliferation. 4'-Bromo-resveratrol reduces lactate production, glucose uptake, and NAD +/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). 4'-Bromo-resveratrol can be used for the research of melanoma .
    4'-Bromo-resveratrol
  • HY-152670
    JC2-11
    1 Publications Verification

    		 NOD-like Receptor (NLR) AIM2 Inflammation/Immunology
    JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1 .
    JC2-11
  • HY-113098
    2-Oxovaleric acid

    		Lactate Dehydrogenase Drug Derivative Metabolic Disease
    2-Oxovaleric acid is an analog of Pyruvate and a substrate inhibitor of Lactate dehydrogenase, exhibiting substrate inhibitory activity against lactate dehydrogenase from Phycomyces blakesleeanus .
    2-Oxovaleric acid
  • HY-124309
    NHI-2

    		Lactate Dehydrogenase Apoptosis Cancer
    NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .
    NHI-2
  • HY-131485
    3-Acetylpyridine adenine dinucleotide, 90%

    3-APAD, 90%; 3-Acetylpyridine NAD, 90%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 90% is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 90% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 90%
  • HY-139319
    LDHA-IN-3
    2 Publications Verification

    		 Lactate Dehydrogenase Cancer
    LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer .
    LDHA-IN-3
  • HY-176798
    NCI-006

    		Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis Cancer
    NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
    NCI-006
  • HY-147216A
    AXKO-0046 dihydrochloride
    5 Publications Verification

    		 Lactate Dehydrogenase Metabolic Disease Inflammation/Immunology Cancer
    AXKO-0046 dihydrochloride, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor. AXKO-0046 dihydrochloride has LDHB inhibitory activity with an EC50 value of 42 nM. AXKO-0046 dihydrochloride can be used for the research of cancer metabolism .
    AXKO-0046 dihydrochloride
  • HY-100742B
    (S)-GNE-140

    		Lactate Dehydrogenase Cancer
    (S)-GNE-140 (Compound 30-S) is the S-enantiomer of GNE-140 (HY-118241). (S)-GNE-140 is an effective lactate dehydrogenase (LDH) inhibitor, with IC50 values of 55 nM for LDHA and 140 nM for LDHB. (S)-GNE-140 can be used in cancer research .
    (S)-GNE-140
  • HY-153129
    EP2 receptor antagonist-2

    		Prostaglandin Receptor Endocrinology
    EP2 receptor antagonist-2 (CID891729) is an antagonist of EP2 receptor. EP2 receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 receptor antagonist-2 also suppresses lactate dehydrogenase (LDH) release induced by N-methyl-D-aspartate (NMDA) .
    EP2 receptor antagonist-2
  • HY-N2177
    3-Dehydrotrametenolic acid

    		Lactate Dehydrogenase Apoptosis Cancer
    3-​Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-​Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-​Dehydrotrametenolic acid induces apoptosis and has anticancer activity .
    3-Dehydrotrametenolic acid
  • HY-147342
    β-Benzamide adenine dinucleotide

    		Drug Metabolite IMPDH Cancer
    β-Benzamide adenine dinucleotide is a biologically active metabolite of benzamide riboside. β-Benzamide adenine dinucleotide is a competitive inhibitor of human NAD kinase with a Ki value of 90 μM, and inhibits human IMPDH with IC50 values of 0.787 μM and 0.884 μM for type I and type II, respectively. β-Benzamide adenine dinucleotide exhibits inhibitory activities against lactate dehydrogenase, glutamate dehydrogenase, and malate dehydrogenase. β-Benzamide adenine dinucleotide can be used for the study of chronic myelogenous leukemia .
    β-Benzamide adenine dinucleotide
  • HY-N2498
    Glomeratose A

    		Lactate Dehydrogenase Others
    Glomeratose A is a lactate dehydrogenase inhibitor, isolated from Polygala tenuifolia .
    Glomeratose A
  • HY-151243
    NCATS-SM1441

    		Lactate Dehydrogenase Cancer
    NCATS-SM1441 (compound 52) is a lactate dehydrogenase (LDH) inhibitor (IC50=40 nM). By inhibiting the activity of LDH, NCATS-SM1441 is able to reduce the production of lactic acid in cancer cells, helping to slow or stop the proliferation of cancer cells. NCATS-SM1441 can be used to study cancer metabolism .
    NCATS-SM1441
  • HY-P2807J
    L-Lactate Dehydrogenase (L-LDH), pig muscle

    		Lactate Dehydrogenase Metabolic Disease
    L-Lactate Dehydrogenase (L-LDH), pig muscle is an L-lactate dehydrogenase found in pig muscle, mainly present in anaerobic tissues (skeletal muscle, red blood cells). L-Lactate Dehydrogenase (L-LDH), pig muscle can interact with acidic liposomes at low pH, causing protein to adsorb onto the liposomes and inhibit enzyme activity. The IC50 values for L-Lactate Dehydrogenase (L-LDH), pig muscle are 0.05 μM for cardiolipin and 1.3 μM for phosphatidylserine liposomes .
    L-Lactate Dehydrogenase (L-LDH), pig muscle
  • HY-139182
    MAGL-IN-3

    		Endogenous Metabolite Metabolic Disease
    CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC50=34.1 nM). It reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells when used at a concentration of 1 μM. CAY10762 (10 mg/kg) increases levels of 2-arachidonoyl glycerol in mouse brain.
    MAGL-IN-3
  • HY-110119
    Galloflavin potassium

    		Lactate Dehydrogenase Apoptosis Others
    Galloflavin potassium is a novel lactate dehydrogenase inhibitor that can be used for the research of cancer. Galloflavin inhibits aerobic glycolysis in PLC/PRF/5 cells and triggers cell death via apoptosis .
    Galloflavin potassium
  • HY-150753
    RS6212
    1 Publications Verification

    		 Oxidative Phosphorylation Lactate Dehydrogenase Cancer
    RS6212 is a specific LDH (lactate dehydrogenase) inhibitor with an IC50 value of 12.03 μM . RS6212 inhibits tumor growth and exhibits potent anticancer activity in multiple cancer cell lines .
    RS6212
  • HY-131485A
    3-Acetylpyridine adenine dinucleotide, 95%

    3-APAD, 95%; 3-Acetylpyridine NAD, 95%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 95% (3-APAD, 95%)is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 95% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 95%
  • HY-178461
    LDHA-IN-10

    		Lactate Dehydrogenase Cancer
    LDHA-IN-10 (Compound HP19) is a Lactate Dehydrogenase-A (LDHA) inhibitor with an IC50 value of 5.2 μM. LDHA-IN-10 reduces lactate production and ATP levels, inhibiting the proliferation of pancreatic cancer cell line PANC-1. LDHA-IN-10 induces G1/S cell cycle arrest and promotes apoptosis. LDHA-IN-10 is promising for research of pancreatic ductal adenocarcinoma (PDAC) .
    LDHA-IN-10
  • HY-123659
    KR-33028

    		Na+/H+ Exchanger (NHE) Apoptosis Cardiovascular Disease Cancer
    KR-33028 is a selective NHE1 inhibitor. KR-33028 reduces hypoxia-induced necrosis and apoptosis in H9c2 cells. KR-33028 inhibits hypoxia-induced increases in cytoplasmic and mitochondrial Ca 2+ levels and cytochrome c release. KR-33028 improves cardiac contractility, reduces lactate dehydrogenase release, and increases tissue ATP, creatine phosphate, and glycogen levels. KR-33028 can be used in research on cancers such as cardioblastoma and cardiovascular diseases such as ischemic stroke .
    KR-33028
  • HY-154865
    Anticancer agent 121

    		Lactate Dehydrogenase Cancer
    Anticancer agent 121, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research .
    Anticancer agent 121
  • HY-154866
    Anticancer agent 122

    		Lactate Dehydrogenase Cancer
    Anticancer agent 122, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research .
    Anticancer agent 122
  • HY-162627
    LDHA-IN-6

    		Lactate Dehydrogenase Cancer
    LDHA-IN-6 (compound 6) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA), with the IC50 of 46 nM. LDHA-IN-6 has antitumor activity .
    LDHA-IN-6
  • HY-162629
    LDHA-IN-7

    		Lactate Dehydrogenase Cancer
    LDHA-IN-7 (compound 21) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA) and LDHB, with the IC50s of 72 nM and 1.2 Μm, respectively .
    LDHA-IN-7
  • HY-169060
    LDHA-IN-8

    		Lactate Dehydrogenase Cancer
    LDHA-IN-8 (Compound 6) is a lactate dehydrogenase (LDHA) inhibitor. LDHA-IN-8 inhibits LDHA catalysis of pyruvate in a dose-dependent manner (EC50 value of 14.54 μM), reduces intracellular lactate levels, and increases intracellular reactive oxygen species (ROS) levels, thereby inhibiting the proliferation of pancreatic cancer cells and lung cancer cells. LDHA-IN-8 holds promise for research in the field of LDHA-related antitumor therapies .
    LDHA-IN-8
  • HY-179027
    LDH-IN-5

    		Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS) SOD Neurological Disease
    LDH-IN-5 is a Lactate Dehydrogenase (LDH) inhibitor with neuroprotective activity. LDH-IN-5 can inhibit cell apoptosis, reduce ROS, MDA production and increases superoxide dismutase (SOD) activity. LDH-IN-5 can be used for the research of neurological disease, such as ischemic stroke .
    LDH-IN-5
  • HY-W013032R
    Oxamic acid (Standard)

    Oxamidic acid (Standard)

    		 Reference Standards Lactate Dehydrogenase Apoptosis Cancer
    Oxamic acid (Standard) is the analytical standard of Oxamic acid. This product is intended for research and analytical applications. Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis[1][2][3].
    Oxamic acid (Standard)
  • HY-168096
    iNOs-IN-5

    		NO Synthase Apoptosis Cardiovascular Disease Neurological Disease
    iNOs-IN-5 (Compound BN-4) is an inhibitor for iNOS with an IC50 of 0.1707 μM, and reduces NO levels in LPS (HT-D1056)-induced RAW264.7 cells. iNOs-IN-5 reduces the hypoxic injury stimulated ROS and lactate dehydrogenase expression, and exhibits anti-necrosis and anti-apoptosis efficacy. iNOs-IN-5 exhibits anti-cerebral ischemia and neuroprotective activities in SD rat models. iNOs-IN-5 is blood-brain barrier penetrable .
    iNOs-IN-5
  • HY-100681R
    GSK2837808A (Standard)

    		Lactate Dehydrogenase Reference Standards Cancer
    GSK2837808A (Standard) is the analytical standard of GSK2837808A (HY-100681). This product is intended for research and analytical applications. GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
    GSK2837808A (Standard)
  • HY-183944
    BN80933

    		NO Synthase Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease
    BN80933 is a selective neuronal nitric oxide synthase (nNOS) inhibitor with a rat Ki of 0.92 μM. BN80933 inhibits lipid peroxidation, and blocks hypoxia-induced lactate dehydrogenase elevation and delayed 8-epiprostaglandin F2α elevation. BN80933 can be used for the research of stroke, and traumatic brain injury .
    BN80933
  • HY-100742AR
    (R)-GNE-140 (Standard)

    		Lactate Dehydrogenase Reference Standards Bacterial Cancer
    (R)-GNE-140 (Standard) is the analytical standard of (R)-GNE-140 (HY-100742A). This product is intended for research and analytical applications. (R)-GNE-140 is a potent inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. (R)-GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. (R)-GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression. (R)-GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer .
    (R)-GNE-140 (Standard)
  • HY-183921
    SQ 32547

    		Calcium Channel Cardiovascular Disease Inflammation/Immunology
    SQ 32547 is a dihydropyridine calcium channel inhibitor with antihypertensive and anti-ischemic activities. SQ 32547 modulates sarcolemmal voltage-dependent calcium channels to inhibit calcium influx, and exerts direct anti-ischemic activity by suppressing myocardial contracture formation and reducing lactate dehydrogenase (LDH) release. SQ 32547 can be used in research related to hypertension, angina pectoris and neurogenic inflammation .
    SQ 32547
  • HY-118241
    GNE-140

    		Lactate Dehydrogenase Cancer
    GNE-140 (Compound 28) is an external racemic mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B). GNE-140 is an effective lactate dehydrogenase (LDH) inhibitor, with the IC50 values for LDHA and LDHB being 9 nM and 30 nM respectively. GNE-140 can be used in cancer research .
    GNE-140
  • HY-180992
    Dual GO/LDHA-IN-1

    		Lactate Dehydrogenase Metabolic Disease
    Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1 .
    Dual GO/LDHA-IN-1
  • HY-100742R
    GNE-140 racemate (Standard)

    		Lactate Dehydrogenase Reference Standards Cancer
    GNE-140 racemate (Standard) is the analytical standard of GNE-140 racemate (HY-100742). This product is intended for research and analytical applications. GNE-140 racemate is an external racemic mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B). GNE-140 racemate is also an effective lactate dehydrogenase (LDH) inhibitor.
    GNE-140 racemate (Standard)
  • HY-181677
    Antibacterial agent 325

    		Bacterial Reactive Oxygen Species (ROS) Lactate Dehydrogenase Infection
    Antibacterial agent 325 is an antibacterial agent. Antibacterial agent 325 exerts potent broad-spectrum antibacterial activity and shows bactericidal activity. Antibacterial agent induces membrane depolarization, disrupts the membrane integrity, increasess ROS production and lipid peroxidation levels. Antibacterial agent 325 inhibits the metabolic activity and Lactate Dehydrogenase (LDH) activity. Antibacterial agent 325 exhibits low drug resistance development in bacteria, low hemolysis and cytotoxicity. Antibacterial agent 325 can be used for the research of bacterial infection .
    Antibacterial agent 325
  • HY-180151
    Antibacterial agent 306

    		Lactate Dehydrogenase Bacterial DNA/RNA Synthesis Reactive Oxygen Species (ROS) Infection
    Antibacterial agent 306 (Compound 8c), a lactate dehydrogenase inhibitor, is a highly effective antibacterial agent, especially effective against Gram-positive bacteria. Antibacterial agent 306 exhibits MIC against Staphylococcus aureus of as low as 1 μg/mL. Antibacterial agent 306 can not only damage membrane integrity and block the replication of DNA by intercalation, but also make reactive oxygen species (ROS) burst. Antibacterial agent 306 can be used for research on anti-multi-drug resistant bacteria .
    Antibacterial agent 306
  • HY-100742BR
    (S)-GNE-140 (Standard)

    		Lactate Dehydrogenase Reference Standards Cancer
    (S)-GNE-140 (Standard) is the analytical standard of (S)-GNE-140 (HY-100742B). This product is intended for research and analytical applications. (S)-GNE-140 (Compound 30-S) is the S-enantiomer of GNE-140 (HY-118241). (S)-GNE-140 is an effective lactate dehydrogenase (LDH) inhibitor, with IC50 values of 55 nM for LDHA and 140 nM for LDHB. (S)-GNE-140 can be used in cancer research .
    (S)-GNE-140 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: